Regarding the inclusion of sequences in a Sequence Listing, the "what/where/when/why/how" can be a source of confusion for many, and, thus, it is one of the most common questions asked (in various forms). As such, below is a brief summary of the main rules related to the requirements for inclusion (or exclusion) of nucleotide and protein sequences in Sequence Listings.
What/Where/When/Why/How Do I Include this Sequence in a Sequence Listing
April 2016 -
Volume 47, Issue 2
NEWSLETTER ARCHIVE
Table of Contents
President's Message by Erik Belt
Read more >
Message from the Editor-in-Chief
Read more >
Alice: Making Step Two Work
Read more >
Grant Submissions and Novelty: A Catch-22 for Startups
Read more >
When are Method/Device Hybrid Claims Indefinite?
Read more >
Update on the Patent Pro Bono Program of New England and Call For Volunteer Attorneys!
Read more >
Saved by the Date? Is Your Pre-AIA Patent Still At Risk for AIA Post Grant Review?
Read more >
Index
6th annual Invented Here! Announcement
Read more >
BPLA Sponsors the New England Innovation Award Program of Smaller Business Association of New England (SBANE)
Read more >
Report on the Giles Rich Moot Court Competition
Read more >
BPLA Writing Competition Accepting Entries
Read more >
Annual Judges' Dinner
Read more >
IP Roundtable with Chief Judge Saris
Read more >
Significant changes to the rules related to european trademarks ¡v three things you should know
Read more >
What/where/when/why/how do I include this sequence in a sequence listing?
Read more >
Members on the move
Read more >
< Back
Member Companies and Firms are Encouraged to Utilize BPLA’s Career Center
Read more >